Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer research reported from D.A. Yardley and co-authors
December 25th, 2008
"The purpose of this study was to evaluate the efficacy and toxicity of the combination of gemcitabine and carboplatin (and with trastuzumab in patients with HER2-positive disease) as first-line treatment for patients with metastatic breast cancer (MBC). Seventy-four patients who had received no previous chemotherapy for MBC were enrolled," scientists writing in the journal Clinical Breast Cancer report. "Patients with HER2-negative breast cancer received treatment with gemcitabine 1000 mg/m(2) intravenously (I.V.) on days 1 and 8 and carboplatin area under the curve (AUC) 5 IN. on day 1. Cycles were repeated every 21 days. Patients with HER2-positive disease...
Source: Women's Health Weekly (2008-12-25)
|
